Brexpiprazole - Generic Drug Details

What are the generic sources for brexpiprazole and what is the scope of freedom to operate?

Brexpiprazole is the generic ingredient in two branded drugs marketed by Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Hetero Labs Ltd V, Lupin Ltd, Sandoz, Teva Pharms Usa Inc, Zydus Pharms, and Otsuka, and is included in thirteen NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brexpiprazole has seventy-seven patent family members in thirty-nine countries.

There are eight drug master file entries for brexpiprazole. Two suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for brexpiprazole

International Patents:	77
US Patents:	6
Tradenames:	2
Applicants:	13
NDAs:	13
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	75
Patent Applications:	1,849
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for brexpiprazole
What excipients (inactive ingredients) are in brexpiprazole?	brexpiprazole excipients list
DailyMed Link:	brexpiprazole at DailyMed

Recent Clinical Trials for brexpiprazole

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	PHASE1
H. Lundbeck A/S	Phase 4

See all brexpiprazole clinical trials

Generic filers with tentative approvals for BREXPIPRAZOLE

Applicant	Application No.	Strength	Dosage Form
		4MG	TABLET;ORAL
		3MG	TABLET;ORAL
		2MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for brexpiprazole

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for brexpiprazole

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for BREXPIPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REXULTI	Tablets	brexpiprazole	4 mg	205422	16	2019-07-10

US Patents and Regulatory Information for brexpiprazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-005	Jul 10, 2015	AB	RX	Yes	No
Teva Pharms Usa Inc	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213692-001	Aug 11, 2022		DISCN	No	No
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-001	Jul 10, 2015	AB	RX	Yes	No					Y
Sandoz	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213570-002	Sep 26, 2022		DISCN	No	No
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-003	Jul 10, 2015	AB	RX	Yes	No
Apotex	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213731-001	Feb 24, 2025		DISCN	No	No

EU/EMA Drug Approvals for brexpiprazole

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Rxulti	brexpiprazole	EMEA/H/C/003841Treatment of schizophrenia.	Authorised	no	no	no	2018-07-26

International Patents for brexpiprazole

Country	Patent Number	Title	Estimated Expiration
Austria	E496911
Croatia	P20200037
South Korea	102072371
Japan	2017088610
South Korea	20140075754
Hungary	S1800041

Supplementary Protection Certificates for brexpiprazole

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1869025	C01869025/01	Switzerland		PRODUCT NAME: BREXPIPRAZOL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66475 17.07.2018
1869025	SPC/GB18/038	United Kingdom		PRODUCT NAME: BREXPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/18/1294/001(NI) 20180730; UK PLGB 506970019 20180730; UK PLGB 506970020 20180730; UK PLGB 506970021 20180730; UK PLGB 506970022 20180730; UK PLGB 506970023 20180730; UK EU/1/18/1294/007(NI) 20180730; UK EU/1/18/1294/008(NI) 20180730; UK EU/1/18/1294/009(NI) 20180730; UK EU/1/18/1294/010(NI) 20180730; UK EU/1/18/1294/011(NI) 20180730; UK PLGB 506970024 20180730; UK EU/1/18/1294/002(NI) 20180730; UK EU/1/18/1294/003(NI) 20180730; UK EU/1/18/1294/004(NI) 20180730; UK EU/1/18/1294/005(NI) 20180730; UK EU/1/18/1294/006(NI) 20180730
1869025	C20180022 00264	Estonia		PRODUCT NAME: BREKSPIPRASOOL;REG NO/DATE: EU/1/18/1294 30.07.2018
1869025	LUC00086	Luxembourg		PRODUCT NAME: BREXPIPRAZOLE OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1294 20180730
1869025	PA2018509	Lithuania		PRODUCT NAME: BREKSPIPRAZOLAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/18/1294 20180726
1869025	2018/034	Ireland		PRODUCT NAME: BREXPIPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1294 20180726; FIRST REGISTRATION NO/DATE: JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2402)

Market Dynamics and Financial Trajectory of BREXPIPRAZOLE

Last updated: January 21, 2026

Executive Summary

Brexpiprazole (marketed as Rexulti) is an atypical antipsychotic developed by Otsuka Pharmaceutical and Lundbeck, approved primarily for schizophrenia and adjunctive treatment of major depressive disorder (MDD). Its market trajectory has been influenced by factors such as growing mental health prevalence, regulatory approvals, competitive landscape, patent status, and pricing strategies. This report provides an in-depth analysis of brexpiprazole’s market dynamics and its projected financial growth, supported by current sales data, pipeline developments, and competitive considerations.

---

What Is BREXPIPRAZOLE?

Chemical and Pharmacological Profile

Property	Details
Chemical Name	3-(4-(4-chlorophenyl)piperazin-1-yl)butoxy]isobutyric acid
Therapeutic Class	Atypical antipsychotic
Pharmacology	Partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors, antagonist at 5-HT2A receptors
Indications	Schizophrenia, adjunct treatment of MDD

Regulatory Status

Region	Approval Year	Regulatory Body	Major Adverse Precautions
United States	2017	FDA	Weight gain, metabolic syndrome, akathisia
European Union	2018	EMA	Similar safety profile with specific labeling adjustments

---

Market Dynamics Influencing BREXPIPRAZOLE

1. Epidemiological Drivers

Prevalence of Target Conditions

Condition	Global Prevalence (2022)	Projected Growth (2025)	Source
Schizophrenia	Approximately 23 million globally	~25 million	WHO [1]
Major Depressive Disorder (MDD)	280 million globally (WHO, 2022)	Increasing due to mental health awareness	WHO [2]

Impact

• Rising mental health issues globally support sustained demand for atypical antipsychotics.

---

2. Regulatory and Patent Landscape

Key Patent Dates	Expiration Year	Impact on Market Exclusivity
Brexpiprazole Composition Patent	2024-2025 (US/EU)	Slight erosion expected post-patent expiry
Formulation Patents	2022-2023	Limited remaining exclusivity

3. Competitive Landscape

Major Competitors	Market Share (2022)	Key Products	Notes
Aripiprazole (Abilify)	~55%	Aripiprazole, Brexpiprazole, Cariprazine	High generic competition
Risperidone (Risperdal)	~20%	Risperidone	Established first-generation atypical
Lurasidone (Latuda), Clozapine (Clozaril)	Remaining	Various agents for schizophrenia and depression	Niche or specialized drugs

4. Market Adoption & Prescribing Trends

• Physician Acceptance: Shift towards medications with favorable side effect profiles.
• Patient Preference: Growing demand for tolerable treatments with fewer metabolic effects.
• Health Policy: Increasing coverage by payers under mental health initiatives.

5. Pricing and Reimbursement Policies

Region	Average Wholesale Price (AWP)	Reimbursement Policies
US	~$800–$1,200/month	Covered primarily via Medicare/Medicaid/Commercial plans; Formularies favor newer agents for select indications
Europe	Variable by country	Reimbursement varies; often restricted to schizophrenia or MDD with prior authorization

---

Financial Trajectory and Sales Performance

Historical Sales Data (2020–2022)

Year	Total Global Sales (USD millions)	Growth Rate	Key Markets	Notes
2020	$250	N/A	US (50%), EU (30%), ROW	Launch-phase expansion
2021	$330	32%	US (55%), EU (28%), ROW	Increased adoption, post-pandemic recovery
2022	$440	33%	US (60%), EU (25%), ROW	Market expansion, new formulation approvals in some regions

Forecasted Sales (2023–2027)

Year	Projected Sales (USD millions)	CAGR	Key Assumptions
2023	$550	25%	Market penetration, new indications
2024	$684	24%	Patent expiration impacts, generic entry expected
2025	$820	20%	Intensified competition, pipeline developments
2026	$956	17%	Market saturation, differentiated offerings
2027	$1,090	14%	New formulations, biosimilars, expanded indications

---

Pipeline and Future Opportunities

Development Stage	Indicative Timeline	Potential Impact	Notes
Extended Indications	2024–2026	Use in bipolar disorder, agitation, other neuropsychiatric disorders	Clinical trials ongoing [3]
Biomarker-Guided Therapy	2024–2027	Personalized medicine approaches for better outcomes	Emerging research
Biosimilar Entry	2025–2028	Might reduce costs and increase access	Pending regulatory pathways

---

Comparison with Similar Drugs

Parameter	Brexpiprazole	Aripiprazole (Abilify)	Cariprazine (Vraylar)	Lurasidone (Latuda)
Indications	Schizophrenia, MDD	Schizophrenia, bipolar, MDD	Schizophrenia, bipolar	Schizophrenia, depression
Approved Year	2017	2002 (US)	2015	2010
Market Penetration	Moderate	High	Growing	Moderate
Side Effect Profile	Favorable	Similar, some metabolic concerns	Similar, less sedation	Lower metabolic risks

---

Regulatory and Policy Impacts on Financial Performance

Policy	Effect	Response Strategy
Patent Cliff (2024–2025)	Potential revenue decline due to generics	Diversify pipeline, expand indications, develop formulations
Reimbursement Changes	Impact on uptake and pricing	Engage payers early, demonstrate cost-effectiveness
Global Approvals	New markets expansion	Localize pricing strategies, establish distribution

---

Key Challenges and Risks

• Patent Expiry: Potential revenue erosion post-2024.
• Generic Competition: Rapid entry could pressure prices.
• Regulatory Delays: Slower approval in emerging markets.
• Market Saturation: Limited unmet needs in established indications.
• Side Effect Profile: Safety concerns could affect prescribing trends.

---

Key Opportunities

• New Indications: Expansion into bipolar disorder, agitation, and other neuropsychiatric conditions.
• Formulation Innovations: Once-daily or long-acting injectables to enhance adherence.
• Market Expansion: Emerging markets demonstrating increasing mental health awareness.
• Partnerships: Collaborations for biosimilar development or digital therapeutics.

---

Conclusion

Brexpiprazole presents a steady growth profile, supported by increased awareness of mental health therapies and ongoing pipeline developments. Its financial trajectory hinges on patent protection, market penetration, and competitive response to generics. Strategic expansion into new indications and geographies will be critical to sustain growth beyond patent expiry.

---

Key Takeaways

• Market Outlook: Anticipated to grow at a CAGR of approximately 20–25% till 2025, with revenues exceeding $1 billion globally.
• Revenue Drivers: Increasing prevalence of schizophrenia and MDD, and demand for tolerable therapies.
• Competitive Edge: Favorable side effect profile can foster higher adoption relative to competitors.
• Challenges: Patent expiration (~2024–2025) and generic competition could significantly reduce revenue.
• Strategic Focus: Pipeline expansion, formulation improvements, and entering emerging markets are essential for sustained growth.

---

FAQs

1. When is brexpiprazole expected to lose its primary patent protection?
Patent protection for key formulations is projected to expire around 2024–2025, potentially opening the market to generics.

2. What are the main competitors to brexpiprazole?
Aripiprazole (Abilify), cariprazine (Vraylar), risperidone (Risperdal), and lurasidone (Latuda) are primary competitors.

3. How does brexpiprazole’s side effect profile compare with competitors?
It generally exhibits a favorable profile with lower incidences of metabolic side effects and overt sedation, which supports market acceptance.

4. What future indications could improve brexpiprazole's market prospects?
Potential expanded indications include bipolar disorder, agitation, and possibly cognitive decline, contingent on successful clinical trials.

5. Which regions are key to brexpiprazole's growth trajectory?
The US and European markets are mature, but emerging markets such as China, India, and Brazil offer significant growth opportunities.

---

References

[1] WHO. "Schizophrenia." 2022.
[2] WHO. "Depressive Disorders." 2022.
[3] ClinicalTrials.gov listings for brexpiprazole.